Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report

Durvalumab plus tremelimumab combination therapy can lead to fulminant immune-mediated myocarditis. This patient's myocarditis was amenable to treatment with high-dose intravenous steroids and mycophenolate.